TGTX TG THERAPEUTICS, INC.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1001316 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY68.8%
TTM net income YoY-76.3%
TTM EPS YoY-75.8%
Revenue 3-yr CAGR67.9%
Net income 3-yr CAGR—
Margins
Gross margin82.7%
Operating margin21.5%
Net margin11.8%
FCF margin9.5%
EBITDA margin21.5%
Returns
ROE18.0%
ROA8.1%
ROIC (approx.)16.4%
Asset turnover0.69x
Leverage & solvency
Liabilities / assets64.1%
Debt / equity1.30x
Current ratio4.50x
Interest coverage4.14x
Cash quality & payout
Operating cash flow / net income0.81x
Accruals ratio1.5%
Payout ratio—
Capex / revenue0.1%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $616.29M | $329.00M | $233.66M | $2.79M | $6.69M |
| Cost of revenue | $100.71M | $38.49M | $14.13M | $265,000 | $790,000 |
| Gross profit | $515.57M | $290.52M | $219.53M | $2.52M | $5.90M |
| R&D expense | $160.22M | $94.29M | $76.19M | $125.35M | $222.58M |
| SG&A expense | $232.03M | $154.30M | $122.71M | $95.48M | $128.09M |
| Operating income | $123.32M | $41.93M | $20.63M | -$218.32M | -$344.77M |
| Interest expense | $26.73M | $24.03M | $12.62M | $10.19M | $5.64M |
| Pretax income | $107.39M | $25.59M | $13.06M | -$223.81M | -$348.10M |
| Income tax | -$339.79M | $2.21M | $390,000 | $0 | $0 |
| Net income | $447.18M | $23.38M | $12.67M | -$223.81M | -$348.10M |
| EBITDA | $123.38M | $42.00M | $20.84M | -$218.01M | -$344.49M |
| EPS (basic) | 3.10 | 0.16 | 0.09 | -1.65 | -2.63 |
| EPS (diluted) | 2.77 | 0.15 | 0.09 | -1.65 | -2.63 |
| Weighted avg. shares (diluted) | 161.41M | 160.34M | 148.51M | 135.41M | 132.22M |
| Balance sheet | |||||
| Cash & equivalents | $79.15M | $179.89M | $92.93M | $102.30M | $298.89M |
| Short-term investments | $62.82M | $131.11M | $124.58M | $59.37M | $15.88M |
| Receivables | $305.63M | $129.19M | $51.09M | $0 | $1.39M |
| Inventory | $125.59M | $110.46M | $39.82M | $0 | — |
| Current assets | $630.76M | $566.36M | $317.94M | $168.27M | $330.96M |
| PP&E, net | — | — | $95,000 | $307,000 | $600,000 |
| Goodwill | — | — | $799,000 | $799,000 | $799,000 |
| Total assets | $1.06B | $577.69M | $329.59M | $193.57M | $379.63M |
| Current liabilities | $153.76M | $90.68M | $53.72M | $53.20M | $65.38M |
| Short-term debt | — | — | — | $0 | $975,000 |
| Long-term debt | $245.65M | $244.43M | $100.12M | $71.14M | $66.79M |
| Total debt | $245.65M | $244.43M | $100.12M | $71.14M | $67.76M |
| Total liabilities | $415.23M | $355.33M | $169.09M | $134.99M | $142.48M |
| Shareholders' equity | $648.02M | $222.36M | $160.50M | $58.59M | $237.15M |
| Net debt | $166.50M | $64.53M | $7.18M | -$31.17M | -$231.12M |
| Shares outstanding | 155.31M | 155.84M | 151.42M | 146.39M | 143.25M |
| Cash flow statement | |||||
| Operating cash flow | -$24.77M | -$40.52M | -$31.41M | -$176.17M | -$295.63M |
| Capital expenditure | $214,000 | $45,000 | $0 | $14,000 | $401,000 |
| Free cash flow | -$24.99M | -$40.56M | -$31.41M | -$176.18M | -$296.04M |
| Investing cash flow | $13.80M | -$1.04M | -$50.65M | -$20.01M | -$332,000 |
| Financing cash flow | -$89.73M | $128.53M | $72.70M | -$391,000 | $41.42M |
| Depreciation & amortization | $59,000 | $68,000 | $211,000 | $303,000 | $282,000 |
| Stock-based compensation | $64.67M | $42.54M | $37.93M | $44.66M | $61.27M |
Free plan shows the latest 5 periods; Pro shows all 15 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.